Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a multicenter retrospective cohort study.

5 ), though these differences did not reach statistical significance, likely due to the limited sample size.

also in 111,027 other papers

Gene mutation/amplification analysis demonstrated that patients with TP53, ERBB2, MYC, or CCND1 alterations showed a trend toward higher tpCR rates (OR >1) compared to patients without these alterations (Fig. 5 ), though these differences did not reach statistical significance, likely due to the limited sample size.

also in 53,322 other papers